Corporate ProfileWe are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate the therapeutic function and direct the fate of hematopoietic cells.
Mar022020March 2, 2020 at 5:00 PM ESTMarch 2, 2020
5:00 PM EST
Feb262020February 26, 2020 at 3:30 PM ESTFebruary 26, 2020
3:30 PM EST